1. FDA. Drug-Diagnostic Co-development Concept Paper. genomics/pharmacoconceptfn.pdf (accessed Oct. 19, 2008).

2. FDA . Table of valid genomic biomarkers in the context of approved drug labels. (accessed Oct. 19, 2008 ).

3. Wagner JA (2008). Strategic approach to fit-for-purpose biomarkers in drug development. Annu Rev Pharmacol Toxicol, 48:631-651.

4. Rifai N, Gillette MA, Carr SA (2006). Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol, 24(8):971-983.

5. Goodsaid F, Frueh FW (2007). Implementing the U.S. FDA guidance on pharma-cogenomic data submissions. Environ Mol Mutagen, 48(5):354-358.

6. Goodsaid F, Frueh F (2006). Process map proposal for the validation of genomic biomarkers. Pharmacogenomics, 7(5):773-782.

7. Goodsaid F, Frueh F (2007). Biomarker qualification pilot process at the US Food and Drug Administration. AAPS J, 9(1):E105-E108.

8. Goodsaid FM, Frueh FW, Mattes W (2008). Strategic paths for biomarker qualification. Toxicology, 245 ( 3 ): 219 - 223 .

9. Anon. (2008) . Public consortium efforts in toxicogenomics. Methods Mol Biol, 460: 221 - 238 .

10. Duarte CG, Preuss HG (1993). Assessment of renal function-glomerular and tubular. Clin Lab Med, 13:33-52.

11. Vaidya VS, Ramirez V, Ichimura T, Bobadilla NA, Bonventre JV (2006). Urinary kidney injury molecule: 1. A sensitive quantitative biomarker for early detection of kidney tubular injury. Am J Physiol Renal Physiol, 290(2):F517-F529.

12. Zhang J, Brown RP, Shaw M, et al. (2008). Immunolocalization of Kim-1, RPA-1, and RPA-2 in kidney of gentamicin-, mercury-, or chromium-treated rats: relationship to renal distributions of iNOS and nitrotyrosine. Toxicol Pathol, 36 (3 ): 397 - 409 .

13. Dieterle F, Maurer E , Suzuki E , Grenet O, Cordier A , Vonderscher J ( 2008 ). Monitoring kidney safety in drug development: emerging technologies and their implications. Curr Opin Drug Discov Dev, 11 ( 1 ): 60 - 71 .

14. Altar CA , Amakye D, Bounos D, et al. ( 2008 ). A prototypical process for creating evidentiary standards for biomarkers and diagnostics. Clin Pharmacol Ther, 83 ( 2 ): 368-371.

15. Wagner JA , Williams SA , Webster CJ ( 2007 ). Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs. Clin Pharmacol Ther, 81(1):104-107.

16. International Committee on Harmonization (ICH) E16. Genomic biomarkers related to drug response: context, structure and format of qualification submissions. (accessed Oct. 19, 2008).

Project Management Made Easy

Project Management Made Easy

What you need to know about… Project Management Made Easy! Project management consists of more than just a large building project and can encompass small projects as well. No matter what the size of your project, you need to have some sort of project management. How you manage your project has everything to do with its outcome.

Get My Free Ebook

Post a comment